Surgical Outcomes of Prepectoral Two-Stage Breast Reconstruction in Patients Treated with Pembrolizumab or CDK4/6 Inhibitors
Pembrolizumab is a promising therapy for TNBC, but its association with increased seromas, major complications, and reoperations warrants further investigation. Use of CDK4/6 inhibitors was not associated with an increased risk of infection following tissue expander placement.
Authors
- Kelly McCann (ORCID: https://orcid.org/0000-0001-8233-6242)
- M. Carter
- Michael R. DeLong (ORCID: https://orcid.org/0000-0001-7143-615X)
- Tahera Alnaseri (ORCID: https://orcid.org/0000-0003-3220-502X)
- Neelesh Gupta (ORCID: https://orcid.org/0009-0000-0728-6476)
- Anne Hall
- Yasmine Ibrahim (ORCID: https://orcid.org/0000-0001-5678-528X)
- M Demirjian
- Lorna Kwan
- Mediget Teshome
Institutions
- University of Southern California (US)
- University of California, Los Angeles (US)
- Los Angeles Medical Center (US)
Publication Details
- Journal
- Plastic & Reconstructive Surgery
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1097/prs.0000000000013032
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00